共 843 条
- [21] Vaishampayan U(2003)A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2103-9
- [22] Negrier S(2007)Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2137-597
- [23] De Meerleer G(2010)Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 6277-3318
- [24] Motzer RJ(2009)A phase I study of sunitinib plus bevacizumab in advanced solid tumors Clin Cancer Res 15 1432-767
- [25] Hutson TE(2009)Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 1-1939
- [26] Tomczak P(2017)Current and emerging treatments for metastatic renal cell carcinoma Curr Cancer Drug Targets 17 591-2697
- [27] Michaelson MD(2017)Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial J Clin Oncol 35 366-13378
- [28] Bukowski RM(2016)Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis Ann Oncol 27 3312-927
- [29] Oudard S(2009)Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 760-3799
- [30] Negrier S(2014)Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 1931-524